Dana-Farber/Harvard Cancer Center Experimental Therapeutics Clinical Trials Network Site (DF/HCC ETCTN Site) - Incorporation of Mayo Clinic Cancer Center as an Affiliated Center
Dana-Farber/Harvard Cancer Center Experimental Therapeutics Clinical Trials Network Site (DF/HCC ETCTN Site) - Incorporation of Mayo Clinic Cancer Center as an Affiliated Center
批准号:
10393266
负责人:
KEITH T FLAHERTY
金额:
$10.0万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-03-13 至 2023-02-28
关键词:
AddressAdministrative SupplementAdvanced Malignant NeoplasmAntibody-drug conjugatesArizonaBiometryCancer CenterCancer Therapy Evaluation ProgramCatchment AreaClinicClinical Cancer CenterClinical InvestigatorClinical TrialsClinical Trials NetworkDNA RepairDana-Farber Cancer InstituteDisciplineDiseaseEnrollmentEnsureFloridaFundingGeneral HospitalsHematologic NeoplasmsImmunooncologyInterventional radiologyInvestigational TherapiesIsraelLeadLeadershipLettersMalignant NeoplasmsMassachusettsMayo Clinic Cancer CenterMedical centerMentorsMentorshipMinority EnrollmentMinority GroupsPathologyPatientsResearchResearch PersonnelRural PopulationScienceSiteSolid NeoplasmTherapeuticTranslatingU-Series Cooperative AgreementsWomanWorkbiomarker-drivencareerearly phase clinical trialimprovedinhibitor/antagonistmemberpatient populationpre-clinicalprogramsrural underservedtranslational scientisttumor metabolism
中文摘要
项目总结/文摘
英文摘要
PROJECT SUMMARY/ABSTRACT
This application is being submitted to request additional funds for Mayo Clinic Cancer Center (MCCC) as an
Affiliated Organization (AO) to the Dana-Farber/Harvard Cancer Center (DF/HCC) Experimental Therapeutics
Clinical Trials Network (ETCTN) Lead Academic Organization (LAO). MCCC investigators, led by Dr. Alex A.
Adjei and representing the Mayo Clinic Rochester, Florida and Arizona sites, have been incorporated into the
DF/HCC LAO Leadership and Steering Committee, Governance Committee and Translational Core.
Additionally, they are participating as disease-focused clinical investigators, with support from MCCC
interventional radiology, pathology and biostatistics. Work conducted under this supplement will facilitate the
continuation and completion of MCCC-led ETCTN trials that address inhibitors of DNA repair and tumor
metabolism, as well as immuno-oncology combinations and antibody drug conjugates across solid tumors and
hematologic malignancies. Emphasis will be placed on the continued mentorship of MCCC early career
investigators, manifested in part by support afforded by the DF/HCC LAO Scholars in Cancer Experimental
Therapeutics (SCET) Program. As an AO, it is anticipated that over the next year, MCCC investigators will
enroll a minimum of 20 patients to ETCTN trials and submit Project Team Member Applications (PTMAs) and
other clinical trial proposals culminating in at least two approved letters of intent (LOIs). MCCC investigators
will also coordinate with DF/HCC to ensure that the LAO consistently demonstrates at least 30% network
participation, with at least 6 trials open in relevant disease-focused disciplines with 10 enrollments per disease
group. Finally, MCCC investigators will also work with DF/HCC to increase the enrollment of under-
represented and rural populations to ETCTN trials by leveraging the catchment area encompassed by MCCC
sites.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
XPO1 inhibitors Selinexor and Eltanexor in Combination with Venetoclax and Decitabine (ASTX727) in AML
-
批准号:10337728
-
项目类别:
-
资助金额:$12.5万
-
财政年份:2021
-
负责人:KEITH T FLAHERTY
-
依托单位:
Dana-Farber/Harvard Cancer Center ET-CTN with Phase I Emphasis
-
批准号:9242737
-
项目类别:
-
资助金额:$71.31万
-
财政年份:2014
-
负责人:KEITH T FLAHERTY
-
依托单位:
Dana-Farber/Harvard Cancer Center Experimental Therapeutics Clinical Trials Network Site (DF/HCC ETCTN Site)
-
批准号:10784840
-
项目类别:
-
资助金额:$255.54万
-
财政年份:2014
-
负责人:KEITH T FLAHERTY
-
依托单位:
Dana-Farber/Harvard Cancer Center ET-CTN with Phase I Emphasis
-
批准号:8725826
-
项目类别:
-
资助金额:$140.0万
-
财政年份:2014
-
负责人:KEITH T FLAHERTY
-
依托单位:
Role of Immune Regulatory Pathways in BRAF targeted therapy In melanoma
-
批准号:8744890
-
项目类别:
-
资助金额:$28.81万
-
财政年份:2014
-
负责人:KEITH T FLAHERTY
-
依托单位:
Regulatory T Cell Compartment
-
批准号:8744883
-
项目类别:
-
资助金额:$30.45万
-
财政年份:2013
-
负责人:KEITH T FLAHERTY
-
依托单位:
Human Specimens
-
批准号:8744886
-
项目类别:
-
资助金额:$29.13万
-
财政年份:2013
-
负责人:KEITH T FLAHERTY
-
依托单位:
Clinically Annotated Human Melanoma for TMEN Research
-
批准号:8555328
-
项目类别:
-
资助金额:$16.56万
-
财政年份:2011
-
负责人:KEITH T FLAHERTY
-
依托单位:
Role of Tumor Stroma in Therapeutic Response and Resistance
-
批准号:8912396
-
项目类别:
-
资助金额:$84.33万
-
财政年份:2011
-
负责人:KEITH T FLAHERTY
-
依托单位:
Role of Tumor Stroma in Therapeutic Response and Resistance
-
批准号:8721884
-
项目类别:
-
资助金额:$82.74万
-
财政年份:2011
-
负责人:KEITH T FLAHERTY
-
依托单位:
Genotype and phenotype predictors in therapy response in renal cell carcinoma
-
批准号:7662800
-
项目类别:
-
资助金额:$50.86万
-
财政年份:2009
-
负责人:KEITH T FLAHERTY
-
依托单位:
Genotype and phenotype predictors in therapy response in renal cell carcinoma
-
批准号:8473174
-
项目类别:
-
资助金额:$42.13万
-
财政年份:2009
-
负责人:KEITH T FLAHERTY
-
依托单位:
Genotype and phenotype predictors in therapy response in renal cell carcinoma
-
批准号:8271303
-
项目类别:
-
资助金额:$44.72万
-
财政年份:2009
-
负责人:KEITH T FLAHERTY
-
依托单位:
Genotype and phenotype predictors in therapy response in renal cell carcinoma
-
批准号:8075445
-
项目类别:
-
资助金额:$44.9万
-
财政年份:2009
-
负责人:KEITH T FLAHERTY
-
依托单位:
Combination Strategies for Angiogenesis Inhibition
-
批准号:6949691
-
项目类别:
-
资助金额:$13.18万
-
财政年份:2004
-
负责人:KEITH T FLAHERTY
-
依托单位:
Combination Strategies for Angiogenesis Inhibition
-
批准号:6718220
-
项目类别:
-
资助金额:$13.17万
-
财政年份:2004
-
负责人:KEITH T FLAHERTY
-
依托单位:
Combination Strategies for Angiogenesis Inhibition
-
批准号:7111100
-
项目类别:
-
资助金额:$13.2万
-
财政年份:2004
-
负责人:KEITH T FLAHERTY
-
依托单位:
Combination Strategies for Angiogenesis Inhibition
-
批准号:7486317
-
项目类别:
-
资助金额:$13.24万
-
财政年份:2004
-
负责人:KEITH T FLAHERTY
-
依托单位:
Role of Immune Regulatory Pathways in BRAF targeted therapy In melanoma
-
批准号:8912399
-
项目类别:
-
资助金额:$29.11万
-
财政年份:--
-
负责人:KEITH T FLAHERTY
-
依托单位:
海外基金